Jennifer E. Amengual
YOU?
Author Swipe
View article: A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study Open
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplant. Therapies include reduction of immunosuppression (RIS), CD20 antibodies and chemoimmunotherapy. R-CHOP yields responses in upwards of 60% of…
View article: Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas
Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas Open
Introduction: Amplification of 9p24.1 (9p+) upregulates PDL-1/2 and JAK2, leading to an immune-privileged tumor microenvironment (TME) and lymphomagenesis. This biology is relevant for lymphomas that harbor 9p+ or rely on JAK/STAT and immu…
View article: Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia
Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia Open
The association between Epstein-Barr virus (EBV) DNAemia after solid organ transplantation (SOT) and posttransplant lymphoproliferative disorder (PTLD) is well described. Published data support preemptive rituximab for EBV DNAemia after bo…
View article: Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit
Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit Open
Alzheimer's disease (AD) diagnosis relies on cerebrospinal fluid (CSF) biomarkers or amyloid PET. Alternatives for AD diagnosis from blood samples are needed to develop a fully-automated early-diagnosis approach, potentially implemented in…
View article: New approach to specific Alzheimer's disease diagnosis based on plasma biomarkers in a cognitive disorder cohort
New approach to specific Alzheimer's disease diagnosis based on plasma biomarkers in a cognitive disorder cohort Open
Background The validation of a combination of plasma biomarkers and demographic variables is required to establish reliable cut‐offs for Alzheimer's disease diagnosis (AD). Methods Plasma biomarkers (Aβ42/Aβ40, p‐Tau181, t‐Tau, NfL, GFAP),…
View article: Targeting Monoallelic <i>CREBBP</i>/<i>EP300</i> Mutations in Germinal Center-Derived B-Cell Lymphoma with a First-in-Class Histone Acetyltransferase Activator
Targeting Monoallelic <i>CREBBP</i>/<i>EP300</i> Mutations in Germinal Center-Derived B-Cell Lymphoma with a First-in-Class Histone Acetyltransferase Activator Open
Inactivating, monoallelic mutations in histone acetyltransferases (HATs) CREBBP / EP300 are common in germinal center (GC) B-cell lymphomas and are implicated in derangements of the GC reaction, evasion of immune surveillance, and disease …
View article: Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma Open
Given the critical importance of concurrent derangements in epigenetic modifiers (CREBBP, EP300, and EZH2) in germinal center (GC) B- and T-cell lymphomas, combined targeting of epigenetic machinery with tazemetostat (EZH2i) and belinostat…
View article: S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL
S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL Open
Large B-cell lymphoma (LBCL) is the most common lymphoma worldwide. About 40% of patients relapse, and many are not eligible for stem cell transplantation, CAR-T cell therapy, or bispecific agents due to chemoresistant and/or aggressive di…
View article: Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
Diagnostic Utility of the 18f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder Open
Background: Post-transplant lymphoproliferative disorder (PTLD) is a major complication following solid organ transplantation (SOT). Epstein-Barr virus (EBV) infection is a significant risk factor for PTLD. Unfortunately, PTLD spans a hete…
View article: Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas Open
Background Amplification of 9p24.1 (9p) upregulates PDL-1/2 and JAK2, leading to an immune-privileged tumor microenvironment (TME) and lymphomagenesis. The 9p amplicon is a key driver of disease in related lymphomas found in 100% of Hodgki…
View article: Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry
Quantitation of tazemetostat in human plasma using liquid chromatography–tandem mass spectrometry Open
To support a phase 1 trial in patients with lymphomas, we developed a liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for tazemetostat quantitation in 20 μL of human plasma. After protein precipitation, chromatographic sep…
View article: Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma Open
Previously, we conducted a Phase I study of the combination of pralatrexate and romidepsin in patients with relapsed/refractory (R/R) lymphomas and subsequently conducted a multicenter Phase II study in patients with untreated or R/R matur…
View article: Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes
Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes Open
Introduction More than half of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) will experience progressive disease after CD19 chimeric antigen receptor T-cell therapy (CART). Circulating tumor DNA profiling has been u…
View article: Outcomes in Minorities with PTCL By Clinical Trial Enrollment
Outcomes in Minorities with PTCL By Clinical Trial Enrollment Open
Background Peripheral T-cell Lymphoma (PTCL) affects a diverse cohort of patients for which survival disparities are evident in minorities. Clinical trial enrollment does not match the demographic diversity represented in PTCL and minoriti…
View article: Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL
Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL Open
Background Outcomes in relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) continue to be suboptimal. In the last decade, several novel agents have been approved; however, their impact on survival remains to be defined. In this mul…
View article: Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma Open
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retro…
View article: How I treat posttransplant lymphoproliferative disorder
How I treat posttransplant lymphoproliferative disorder Open
Posttransplant lymphoproliferative disorder (PTLD) is an important and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). Given the heterogeneity of PTLD and the risk of infec…
View article: OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS Open
Introduction: TP53 alterations are associated with poor prognosis in mantle cell lymphoma (MCL). In trials of intensive chemotherapy and autologous hematopoietic cell transplant (auto-HCT), patients (pts) with TP53 mutations had an overall…
View article: S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL
S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL Open
Large B-cell lymphoma (LBCL) is the most common lymphoma worldwide. About 40% of patients relapse, and most are not eligible for transplantation due to chemoresistant disease, advanced age, comorbidities, or lack of access to tertiary care…
View article: ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA
ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA Open
New findings have identified several DLBCL clusters, including the EZB-GC-DLBCL subtype that is enriched in mutations of CREBBP, EP300, and EZH2 (Wright 2020; Schmitz 2018; Chapuy 2018). More than 1/3 of patients with EZB-DLBCL will relaps…
View article: Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL Open
Background: Conventional salvage chemotherapy has limited efficacy in relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). In the last decade, several novel agents have been approved; however, their impact on real world survival re…